Get the latest tech news
Not all cancer patients need chemo — Ataraxis AI raised $20M to personalize treatment
Ataraxis AI has raised a $20.4 million Series A to make cancer treatment more personalized.
Ataraxis AI now plans to launch their first commercial test, for breast cancer, to U.S. oncologists in the coming months, its co-founder Jan Witowski tells TechCrunch. To bolster the launch and expand into other types of cancer, the startup has raised a $20.4 million Series A, it told TechCrunch exclusively. His investigative reporting has led to U.S. government sanctions against four tech companies, including China’s largest AI firm.
Or read this on TechCrunch
